Genomic Health Announces Availability of Oncotype DX® Prostate Cancer Test with Potential to Triple the Number of Patients Who Can Confidently Choose Active Surveillance and Avoid Side Effects of Invasive Treatments

Groundbreaking Results from University of California, San Francisco (UCSF) Clinical Validation Study Presented at American Urological Association (AUA) Annual Meeting
First-of-its-Kind, Biopsy-Based Test Developed and Validated in Seven Studies Including More Than 1,100 Patients

Genomic Health, Inc. (GHDX) is making its Oncotype DX® prostate cancer test available to physicians and their patients today following the presentation by the University of California, San Francisco (UCSF) of a positive clinical validation study at the 2013 American Urological Association (AUA) Annual Meeting in San Diego. 

Teva and Alexza Announce Teva’s License to Market ADASUVE® in the U.S.

Adasuve® (loxapine) inhalation powder is approved in the U.S. for the acute treatment
of agitation associated with schizophrenia and bipolar disorder

Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd (TEVA), and Alexza Pharmaceuticals, Inc. (ALXA) announced today that the companies have entered into an exclusive U.S. license and supply agreement for ADASUVE (loxapine) inhalation powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Teva will be responsible for all U.S. commercial and clinical activities for ADASUVE, including U.S. post-approval clinical studies, and has gained rights to conduct additional clinical trials of ADASUVE for potential new indications in neurological disorders. Alexza will be responsible for manufacturing and supplying ADASUVE to Teva for commercial sales and clinical trials.

Cayden Resources Provides a Corporate Update

Cayden Resources Inc. (TSX VENTURE:CYD) ("Cayden" or the "Company") is pleased to provide a corporate update to its shareholders.

Cash position and sustainability

The Company currently has a strong cash position with over two years of operating capital. The current treasury including near-term receivables is approximately $15 million and Cayden is budgeting to have in excess of $9 million in the treasury in December, after the 2013 drill programs and property payments are completed.

Cayden has the unique opportunity to obtain additional non-dilutive funding with the potential future sale of its Las Calles concession. The concession represents a strip of land, located in between the operating Los Filos and El Bermejal pits that make up Goldcorp's (TSX-G) Los Filos mine.

WestJet reports record net earnings of $91 million, up 33 per cent